Sanofi, a healthcare company, engages in the research, development, manufacture and marketing of therapeutic solutions worldwide. Principal Activities The company is organized around three principal activities: Pharmaceuticals, Vaccines Via Sanofi Pasteur, and Animal Health Via Merial. The company invests in various activities, such as Diabetes, Cardiovascular, Rare Diseases and Multiple Sclerosis (MS), Consumer Health Care, Oncology, Generics, Established Prescription Products, Vaccines, and Animal Health. Pharmaceutical Products Within the pharmaceuticals business, the company’s primary marketed products could be grouped into the key fields of diabetes, cardiovascular disease, rare diseases, multiple sclerosis and oncology. The company has also developed a presence in consumer health care and generics. Diabetes Solutions The company’s principal diabetes products are Lantus, and Toujeo, long acting analogs of human insulin; Amaryl, a sulfonylurea; Apidra, a rapid acting analog of human insulin; Insuman, a human insulin; and Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist. Lantus Lantus (insulin glargine) is a long-acting analog of human insulin, indicated for once-daily subcutaneous administration in the treatment of adult patients with type 2 diabetes who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients (label extension for pediatric use was granted in the E.U. in 2012) aged two years with type 1 diabetes. Lantus is the most-studied basal insulin with approximately 10 years of clinical evidence in diabetes treatment and a safety profile. Lantus could be administered subcutaneously using syringes or specific pens, such as Lantus SoloSTAR, a pre-filled disposable pen available in approximately 120 countries worldwide, which combines a low injection force of approximately 80 units per injection with ease of use; AllSTAR, the first reusable insulin pen developed specially for people with diabetes in emerging markets, indicated for use with the company’s insulin portfolio. AllSTAR is available in various countries, mostly in emerging markets. Lantus is available in approximately 120 countries worldwide. The major countries for sales of Lantus in 2015 were the U.S., China, France and Germany. The company has patents protecting the Lantus formulation and devices, which deliver Lantus. Toujeo The company’s next generation basal insulin Toujeo (insulin glargine 300 units/mL) has been granted marketing authorization by three major regulatory authorities, such as the FDA (February 25, 2015), the European Commission (April 28, 2015) and the Japanese Ministry of Health, Labor and Welfare (J-MHLW) where its approved brand name is Lantus XR (June 30, 2015). Toujeo is available in the Toujeo SoloSTAR, a disposable prefilled pen, which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR. The maximum single injection dose of 80 IU meets the needs of the majority of patients on basal insulin in the U.S., who require 80 IU or less per day. Toujeo has been launched in 20 countries, including the U.S., Germany, the U.K. and Japan. Toujeo is pending marketing authorization with other health authorities worldwide and it is expected that an additional 24 countries, including France, Italy and Spain would launch Toujeo in 2016 making this next-generation basal insulin treatment for type 1 and type 2 diabetes available. Apidra Apidra (insulin glulisine) is a rapid-acting analog of human insulin. Apidra is indicated for the treatment of adults with type 1 or type 2 diabetes for supplementary glycemic control. Apidra has a more rapid onset and shorter duration of action than fast-acting human insulin and can be used in combination with long-acting insulins, such as Lantus for supplementary glycemic control at mealtimes. Apidra can be administered subcutaneously using syringes or specific pens, including the Apidra SoloSTAR disposable pen. Apidra is available in approximately 100 countries worldwide. Insuman Insuman (human insulin)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for SNYN.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.